Drew Weissman Patents & Innovation Profile — PatSnap Eureka
Drew Weissman: Patent Portfolio & Innovation Analysis
Drew Weissman is a physician-scientist and Professor of Medicine at the Perelman School of Medicine, University of Pennsylvania, associated with 533 patents spanning nucleoside-modified mRNA vaccines, lipid nanoparticle delivery systems, and foundational mRNA immunology — work recognised by the 2023 Nobel Prize in Physiology or Medicine. His published body of 183 papers, dating from 2004 onwards, constitutes some of the most widely cited prior art in the modern mRNA therapeutics field.
Top Cited Publications by Year
Peak citation impact: 2018 review paper with 3,308 citations — the defining reference for the mRNA vaccine field.
Drew Weissman's Publication Impact
183 published papers with citation counts placing key works among the most influential in modern vaccinology — the 2018 mRNA vaccines review alone has 3,308 citations.
Citation Impact by Publication
The 2018 mRNA vaccines review is the most cited work, followed by the 2021 infectious diseases review (1,133 citations) and the foundational 2004 TLR3 paper (956 citations).
Research Theme Distribution
Weissman's 183 papers cluster into three coherent themes: foundational mRNA immunology, nucleoside-modified vaccine development, and LNP delivery & therapeutic applications.
Core Areas of Innovation
Drew Weissman's research and patent activity spans three deeply interconnected technology domains that together form the complete mRNA-LNP vaccine and therapeutic platform.
Foundational mRNA Immunology
Core domainResearch addressing why synthetic mRNA triggers innate immune responses and how nucleoside modification — specifically incorporating pseudouridine — suppresses immune sensing while enhancing protein translation. This domain established the molecular basis for the entire nucleoside-modified mRNA therapeutics field.
- mRNA Is an Endogenous Ligand for Toll-like Receptor 3 (2004)
- Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation (2011)
- Modified nucleosides limit activation of the 2'-5'-oligoadenylate synthetase/RNase L pathway (2011)
Nucleoside-Modified mRNA Vaccines
Primary domainSystematic development of mRNA vaccine candidates against high-priority pathogens including HIV, SARS-CoV-2, Zika, influenza, herpes simplex virus, cytomegalovirus, and malaria. This work demonstrated that nucleoside-modified mRNA-LNP vaccines elicit potent humoral and cellular immune responses, including broadly neutralising antibodies and T follicular helper cell activation.
- Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination (2017)
- Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses (2018)
- SARS-CoV-2 mRNA-LNP vaccine demonstrating strong cellular and humoral immunity (2020)
Lipid Nanoparticle Delivery & Therapeutic mRNA
Expanding domainResearch into LNP adjuvanticity, thermostability, scalable manufacturing, and cell-type-specific delivery of mRNA payloads. Beyond vaccines, this domain extends to therapeutic mRNA applications including liver regeneration via hepatocyte growth factor, VEGF-C mRNA for lymphedema reversal, STING mRNA as a cancer immunotherapy agent, and nanocarrier delivery to the injured brain.
- Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines (2021)
- Engineered CD4+ cell-homing mRNA-LNPs for potential HIV therapy (2021)
- Throughput-scalable LNP manufacturing for translational production (2023)
Drew Weissman's Most Cited Research Publications
183 papers indexed — with a combined citation count across key works exceeding 7,800, placing Weissman's output among the most impactful in modern vaccinology and RNA therapeutics.
| Title | Year | Citations | Key Institutions |
|---|---|---|---|
| mRNA vaccines — a new era in vaccinology | 2018 | 3,308 ↑ | Duke Human Vaccine Institute; University of Pennsylvania |
| mRNA vaccines for infectious diseases: principles, delivery and clinical translation | 2021 | 1,133 ↑ | Carnegie Mellon University; University of Pennsylvania |
| mRNA Is an Endogenous Ligand for Toll-like Receptor 3 | 2004 | 956 ↑ | University of Pennsylvania |
| Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation | 2011 | 807 ↑ | University of Pennsylvania; University of Bonn |
| Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines | 2021 | 633 ↑ | University of Pennsylvania; Acuitas Therapeutics; BioNTech; Mount Sinai |
| Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination | 2017 | 492 ↑ | NIH; University of Pennsylvania; Duke; Acuitas; BioNTech |
Foundational mRNA Immunology
The earliest strand of Weissman's research explains why synthetic mRNA triggers immune responses and demonstrates that nucleoside modification — specifically pseudouridine incorporation — suppresses innate immune sensing while improving protein translation. The 2004 TLR3 paper and 2011 HPLC purification paper are the foundational prior art documents for the entire field.
Nucleoside-Modified Vaccine Development
Building on the immunological foundations, Weissman's laboratory systematically developed mRNA vaccine candidates against HIV, Zika, SARS-CoV-2, influenza, cytomegalovirus, herpes simplex virus, and malaria — demonstrating potent T follicular helper cell and germinal centre B cell responses across multiple pathogen models.
LNP Delivery & Therapeutic Applications
A third cluster addresses the delivery infrastructure enabling mRNA vaccine function — covering LNP adjuvanticity, thermostability, scalable manufacturing, and therapeutic applications including liver regeneration, lymphedema reversal via VEGF-C mRNA, STING mRNA cancer immunotherapy, and nanocarrier delivery to the injured brain.
Drew Weissman's Research Collaborators
Key Institutional Collaborators
Collaboration Highlights
Weissman's co-authorship network reflects the consortium-based development model typical of mRNA vaccine science — spanning academic medical centres, commercial LNP technology developers, and government research institutions. This distributed collaboration structure means that inventorship and assignment rights in jointly developed technologies may be distributed across multiple institutions and commercial partners, a critical consideration for IP teams conducting FTO or licensing analysis.
- University of Pennsylvania (Perelman School of Medicine) Primary institution
- Duke Human Vaccine Institute Co-author: 2018 review (3,308 cit.)
- Acuitas Therapeutics (Vancouver) Co-author: Zika, LNP efficacy papers
- BioNTech RNA Pharmaceuticals Co-author: Zika, germinal centre, LNP
- National Institutes of Health Co-author: Zika vaccine study (2017)
- Carnegie Mellon University Co-author: 2021 review (1,133 cit.)
Why Drew Weissman's Portfolio Matters
Strategic implications for patent attorneys, in-house IP teams, and R&D strategists operating in the mRNA-LNP technology landscape.
FTO Considerations
The nucleoside-modified mRNA and LNP delivery technology domain is one of the most actively contested in modern biotech IP. Weissman's research established multiple concepts underpinning fundamental patent claims — including nucleoside modification strategies to evade innate immune sensing, HPLC purification protocols for therapeutic mRNA, and the use of LNPs to deliver mRNA-encoded immunogens. Any organisation seeking to develop, manufacture, or commercialise mRNA vaccines or therapeutics must conduct careful prior art analysis accounting for this foundational layer of IP. The published literature alone, from 2004 onwards, constitutes a significant body of prior art that could affect claim scope in later patent applications.
Prior Art Relevance
The 2004 TLR3 ligand paper (956 citations) and the 2011 pseudouridine-modification and HPLC purification papers (807 citations) are particularly significant prior art anchors. They predate many subsequent patent applications in the field by years, and their combined citation counts confirm that the broader IP community treats them as foundational references. Patent examiners and litigators should be aware of these publications when evaluating claim novelty or non-obviousness in contested mRNA patents. The 2018 review (3,308 citations) similarly functions as a definitive prior art reference for the consolidated mRNA vaccine field.
Drew Weissman Patent & Research Profile: FAQs
Analyse Drew Weissman's Full IP Landscape in PatSnap Eureka
Access the complete 533-patent portfolio, full-text literature corpus, citation network, FTO analysis tools, and real-time monitoring for the mRNA-LNP technology domain — all in one AI-native platform.
References & External Resources
- 1. Weissman et al. "mRNA vaccines — a new era in vaccinology." Nature Reviews Drug Discovery, 2018. View in PatSnap Eureka
- 2. Weissman et al. "mRNA vaccines for infectious diseases: principles, delivery and clinical translation." 2021. View in PatSnap Eureka
- 3. Weissman et al. "mRNA Is an Endogenous Ligand for Toll-like Receptor 3." 2004. View in PatSnap Eureka
- 4. Weissman et al. "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation." 2011. View in PatSnap Eureka
- 5. Weissman et al. "Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination." 2017. View in PatSnap Eureka
- 6. Weissman et al. "Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines." 2021. View in PatSnap Eureka
- 7. USPTO Patent Search — www.uspto.gov/patents/search
- 8. EPO Espacenet Patent Search — worldwide.espacenet.com
- 9. WIPO PATENTSCOPE — patentscope.wipo.int
PatSnap Eureka searches 208M+ patents and papers to answer instantly.